Navigation Links
Amgen's Full Year 2012 Revenues Increased 11 Percent To $17.3 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $6.51
Date:1/23/2013

12FY '11YOY ΔUSROWTOTALTOTALTOTALNeulasta®/ NEUPOGEN®$4,214

$1,138

$5,352$5,2123%Neulasta®3,207

885

4,0923,9524%NEUPOGEN®1,007

253

1,2601,2600%Enbrel®3,967

269

4,2363,70114%Aranesp®782

1,258

2,0402,303(11%)EPOGEN®1,941

0

1,9412,040(5%)Sensipar® / Mimpara®639

311

95080818%Vectibix®122

237

35932211%Nplate®214

154

36829724%XGEVA®644

104

748351*Prolia®292

180

472203*Other 0

173

17358*Total product sales$12,815

$3,824

$16,639$15,2959%* Change in excess of 100%Operating Expense and Tax Rate Analysis, on an Adjusted Basis

  • Cost of Sales, excluding the impact of the Puerto Rico excise tax, increased 0.3 points to 14.7 percent in the fourth quarter of 2012 and increased 0.4 points to 14.4 percent for the full year due to product mix, offset partially by manufacturing efficiencies and higher average net sales price. 
  • Research & Development (R&D) expenses increased 9 percent in the fourth quarter of 2012 driven by later-stage clinical programs, primarily AMG 145 and romosozumab (AMG 785). For the full year, R&D expenses increased 6 percent driven by later-stage clinical programs, primarily AMG 145 and romosozumab (AMG 785), offset partially by reduced expenses associated with marketed product support.
  • Selling, General & Administrative (SG&A) expenses increased 13 percent in the fourth quarter of 2012 driven by higher ENBREL profit share expenses and international expansion.  ENBREL profit share expenses increased 27 percent to $414 million in the fourth quarter.  For the
    '/>"/>

  • SOURCE Amgen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. IRIDEX Announces Preliminary Unaudited Revenues for 2012 Fourth Quarter and Year End
    2. MDHI Receives Term Sheet for Working Capital and Acquisition Financing -- Company Hits Profitability on Recurring Revenues
    3. Groupe Athena, Inc. Reports Record First Quarter Revenues, Adoption Of IFRS Accounting Standard In Anticipation Of Applying For Listing On The NASDAQ Bulletin Board
    4. InfuSystem Holdings, Inc. Reports $14.1 Million of Revenues for the Second Quarter of 2012; Announces Annualized Cost Savings in Excess of $1 million
    5. AMILPAR - Revenues Grow 18% and EBITDA Increases 19% in 1H12
    6. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
    7. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
    8. CitiusTech Announces H1 2012 Results - 65% Growth in Half Year Revenues
    9. Herborium Group Reports Record 6 Month Revenues
    10. InfuSystem Holdings, Inc. Reports $14.3 Million of Revenues And $1.6 Million Of EBITDA For The First Quarter Of 2012
    11. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)...  The board of directors of VirtualScopics, Inc. (NASDAQ: ... trial imaging solutions, today announced that James Groff ... immediately.  Mr. Groff has held the role of acting ... in January 2006 as an accounting manager and was ... the board of VirtualScopics asked Jim to assume the ...
    (Date:8/21/2014)... 21, 2014  SI-BONE, Inc. ( San Jose, ... the use of the iFuse Implant System, ® ... of the sacroiliac (SI) joint, announced that Priority Health ... its Lumbar Fusion Medical Policy No. 91590-R4 providing positive ... policy states that the fusion procedure, which employs the ...
    (Date:8/20/2014)... 2014  The National Association of Drug Diversion ... by the real-time, pseudoephedrine (PSE) blocking system in ... Exchange (NPLEx), automatically blocks unlawful PSE sales and ... and make arrests. Data released by NPLEx shows ... blocked the sale of more than 23,478 boxes of ...
    Breaking Medicine Technology:VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Kentucky's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
    ... 2011 As the Joint Select Committee on Deficit Reduction ... the next ten years, the Pharmaceutical Care Management Association ... committee opportunities to leverage greater use of pharmacy benefit management ... costs over that same time period. "Everyone in ...
    ... Aug. 31, 2011 LifeVantage Corporation (OTCBB: ... supplement, announced today that Douglas C. Robinson, the Company,s ... the Company,s Chief Science Officer, will be presenting at ... be held on September 11-13, 2011, at the Waldorf ...
    Cached Medicine Technology:PCMA Outlines $100 Billion in Prescription Drug Savings for Deficit Reduction Committee 2PCMA Outlines $100 Billion in Prescription Drug Savings for Deficit Reduction Committee 3LifeVantage to Present at Rodman & Renshaw Annual Global Investment Conference 2
    (Date:8/21/2014)... San Diego, CA (PRWEB) August 21, 2014 ... this year, is a short but powerful collection of ... meant to uplift and inspire other budding entrepreneurs on ... honored and proud to announce the inclusion of President ... and insight from highly successful and self-made celebrities such ...
    (Date:8/21/2014)... ERT, a leading global solution ... endpoint data collection, today opened registration for ... Product Value with Optimized Endpoints. The ... developers to network with leading researchers as ... implementing, and justifying effective strategies for collecting ...
    (Date:8/21/2014)... Early diagnosis of diabetic peripheral neuropathy is important ... group at the Fourth Affiliated Hospital of Kunming ... sought to establish a sensitive index for nerve ... neuropathy in 500 patients with diabetes mellitus. Nerve ... longer, sensory nerve conduction velocity was slower, and ...
    (Date:8/21/2014)... 21, 2014 The ... Vascular Devices Market by Angioplasty Balloon ... (IVUS, OCT), IVC Filter (Retrievable), Endovascular ... analyzes and studies the major market ... U.S. and Canada. , Browse 108 ...
    (Date:8/21/2014)... (PRWEB) August 21, 2014 Artisan Business ... & Investment Exploratory Delegation to southern China October 12-19, ... to explore the rapid growing cities of Shenzhen and ... will have the rare opportunity to meet with major ... during a short weeklong time frame. , The ...
    Breaking Medicine News(10 mins):Health News:Earth Source Organics President Audrey Darrow Featured in New David Mullings Book 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 4Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 5Health News:Artisan Business Group announces 2014 EB-5 Investment Trade Mission to China 2
    ... June 5 (HealthDay News) -- The human body has two ... and the "good" brown kind that burns them. Now, researchers ... fat to help people lose weight. "We are now ... treating obesity and diabetes," study lead author Dr. Aaron Cypess, ...
    ... -- ASCO Abstract #CRA9015. Flaxseed provides no benefit in ... and postmenopausal women, according to a Mayo Clinic ... (NCCTG) study. The randomized, placebo-controlled study was conducted on ... no statistically significant difference in mean hot flash scores ...
    ... a study that included nearly 18,000 children who had cancer, ... associated with a subsequent primary neoplasm (a new tumor) at ... neoplasms (related to the genital or urinary tract organs), according ... JAMA , a theme issue on cancer. The study is ...
    ... a woman,s skin wrinkles are during the first few years ... will be presented Monday at The Endocrine Society,s 93rd Annual ... the skin may offer a glimpse of the skeletal well-being, ... reproductive endocrinologist and associate professor at Yale School of Medicine, ...
    ... HealthDay Reporter , FRIDAY, June 3 (HealthDay News) -- U.S. ... little chance the deadly new strain of E. coli bacteria ... impact here. "This outbreak has not affected the ... Administration,s Regional Operations, said during a Friday afternoon news conference. ...
    ... -- A mutant gene long thought to accelerate tumor ... of malignant cells, showing promise for novel cancer therapies, ... will be presented by Mayo Clinic researcher Honey Reddi, ... Dr. Reddi,s discovery could have widespread implications in cancer ...
    Cached Medicine News:Health News:Brown Fat Cells May One Day Help Combat Obesity 2Health News:Mayo Clinic: Flaxseed no cure for hot flashes during breast cancer or menopause 2Health News:Childhood cancer survivors at increased risk of certain tumors in middle-age 2Health News:Childhood cancer survivors at increased risk of certain tumors in middle-age 3Health News:Severity of facial wrinkles may predict bone density in early menopause 2Health News:Officials: U.S. Not Affected by European E. Coli Outbreak 2Health News:Officials: U.S. Not Affected by European E. Coli Outbreak 3Health News:Fighting cancer with cancer: Mayo Clinic finds promising use for thyroid cancer gene 2
    ... The Portex® Thermovent® T helps provide protection ... It is small and extremely lightweight making it ... adults. With a high rate of heat and ... secretion retention., ,All HMEs and filters have ...
    circuitGuard™ Products are available in filter or filter/HME styles., ,High quality air cushion anesthesia masks may be packaged with any circuitGuard™ product....
    ... Since 1991 Intersurgical Incorporated ... filters, heat and moisture ... therapy products, hand-held nebulizers ... of accessories and connectors ...
    ... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
    Medicine Products: